Skip to content

High Energy Formula Feeding in Infants With Congenital Heart Disease

High Energy Formula Feeding in Infants With Congenital Heart Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01850784
Enrollment
100
Registered
2013-05-09
Start date
2013-02-28
Completion date
2014-10-31
Last updated
2013-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Failure, Neurodevelopmental Disorder

Keywords

Congenital heart disease, Growth,Neurodevelopment

Brief summary

High energy formula more positively affect growth in infants with congenital heart disease compared to standard formula

Detailed description

Infants with congenital heart disease (CHD) usually show growth retardation as they can not intake enough calorie due to fluid restriction. We hypothesize that high energy formula more positively affect growth in infants with congenital heart disease compared to standard formula

Interventions

DIETARY_SUPPLEMENTHigh energy formula

The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)

DIETARY_SUPPLEMENTStandard formula

The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)

Sponsors

Dr. Sami Ulus Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
8 Days to 6 Months
Healthy volunteers
No

Inclusion criteria

* infants \>35 weeks of gestational age * infants with CHD * İnfants fed with formula feeding

Exclusion criteria

* Major congenital abnormalities except CHD * infants could not be fed enterally

Design outcomes

Primary

MeasureTime frame
Weight gain6 weeks

Secondary

MeasureTime frameDescription
Neurodevelopmental evaluation18 monthsNeurodevelopmental evaluation will be assessed by Bayley-II Scale at corrected age of 12-18 months.

Countries

Turkey (Türkiye)

Contacts

Primary ContactDilek Dilli, Assoc Prof
dilekdilli2@yahoo.com00903126243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026